In an article subheaded "Current Gaucher's Gene Therapy Trials," onpage 3 of its Friday, April 18 issue, BioWorld stated in error thatGenetic Therapy Inc. (GTI) of Gaithersburg, Md., had already beguntreating patients. In fact, the company is still awaiting FDA approval,following clearance by the RAC in June 1993.GTI informed BioWorld that it anticipates treating the first of 15planned patients "in the near term" at the Los Angeles Children'sHospital and at NIH. The protocol uses a retroviral vector toincorporate a normal cerebrosidase gene ex vivo into the patient'sprecursor blood cells. Transformed cells are then reinjected toreconstitute functioning blood-cell populations.

(c) 1997 American Health Consultants. All rights reserved.